Harvard Apparatus Regenerative Technology 3Q 2026: Revenue $145K, EPS ($0.08) — 10-Q Summary
Harvard Apparatus Regenerative Technology reported 3Q 2026 revenue of $145K, up 18% YoY, and a net loss of $1.46M, down 14%. Growth came from higher shipments to Health Regen, while R&D costs fell 67% due to lower clinical trial expenses. The company expects current cash to fund operations into 1Q 2027 but needs additional capital.
